Osteoporosis

A one-time measurement of follicle-stimulating hormone during pre- or perimenopause may serve as an independent predictor of imminent bone loss, particularly at the lumbar spine, during the menopause transition, according to findings published in the Journal of Bone and Mineral Research.

For women who had a hysterectomy and their ovaries removed, estrogen therapy was associated with long-term benefits if the therapy began before the age of 60 years, but it led to adverse events in those aged 70 years or older, according to a study published in the Annals of Internal Medicine.

Endocrine Today has compiled a list of the top 10 news reports posted so far in of 2019.

Postmenopausal women with osteoporosis who received a regimen of three separate, 6-month cycles of daily teriparatide followed by one subcutaneous injection of denosumab experienced a moderate gain in cortical bone mineral density at 18 months that was not observed among similar women who received the standard regimen of 18 months of teriparatide followed by 18 months of denosumab, according to findings published in the Journal of Bone and Mineral Research.

For patients with osteoporosis, no drug treatment was associated with reduced mortality rates, according to a study published in JAMA Internal Medicine. These treatments should, therefore, only be recommended to decrease fracture risk.

Radius Health has initiated enrollment for a phase 3 clinical trial to assess the safety and efficacy of a wearable abaloparatide-transdermal patch in the treatment of postmenopausal women with osteoporosis at high risk for fracture, the company announced in a press release.

Identifying prevalent vertebral fractures on lateral spine images at the time of a bone density test influenced the subsequent use of osteoporosis therapies among patients, with the greatest impact observed among patients without osteoporosis by bone mineral density criteria, according to findings published in the Journal of Bone and Mineral Research.

Medication adherence for patients with rheumatoid arthritis, gout and osteoporosis was heavily influenced by the degree of trust patients had in their physician, as well as medication properties and patient capabilities, according to data published in Arthritis Care & Research.

More than one-third of patients with COPD worldwide may have osteoporosis, according to a systematic review and meta-analysis published in CHEST.

The therapeutic arsenal for osteoporosis has expanded dramatically since the early 1980s, when the only options were estrogen for women and calcium and vitamin D for men. Today, the picture is much different. Available therapies include estrogen, raloxifene, four different bisphosphonates, the anabolics teriparatide and abaloparatide, and the monoclonal antibody denosumab.